Get the Stockscreener App
11.75
0.00%
0.00
After Hours:
11.65
-0.10
-0.85%
Sutro Biopharma Inc stock is traded at $11.75, with a volume of 155.95K.
It is up +0.00% in the last 24 hours and up +38.32% over the past month.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
See More
Previous Close:
$11.75
Open:
$11.7
24h Volume:
155.95K
Relative Volume:
1.30
Market Cap:
$100.10M
Revenue:
$153.73M
Net Income/Loss:
$-106.79M
P/E Ratio:
-6.6011
EPS:
-1.78
Net Cash Flow:
$-115.93M
1W Performance:
+1.56%
1M Performance:
+38.32%
6M Performance:
+49.78%
1Y Performance:
-39.74%
1-Day Range:
$11.14
$11.99
1-Week Range:
$10.15
$12.32
52-Week Range:
$5.231
$21.50
Sutro Biopharma Inc Stock (STRO) Company Profile
Name
Sutro Biopharma Inc
Sector
Industry
Phone
650-392-8412
Address
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare STRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STRO
Sutro Biopharma Inc
|
11.75 | 100.10M | 153.73M | -106.79M | -115.93M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-17-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-14-25 | Downgrade | BofA Securities | Buy → Underperform |
| Mar-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Mar-14-25 | Downgrade | Wedbush | Outperform → Neutral |
| May-08-24 | Initiated | BofA Securities | Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-06-23 | Initiated | Oppenheimer | Outperform |
| Mar-21-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-18-22 | Resumed | Wells Fargo | Overweight |
| Jun-18-21 | Initiated | H.C. Wainwright | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| Sep-02-20 | Initiated | Jefferies | Buy |
| Jul-16-20 | Initiated | Wells Fargo | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Oct-07-19 | Initiated | BTIG Research | Buy |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| Apr-29-19 | Initiated | H.C. Wainwright | Buy |
| Oct-22-18 | Initiated | JMP Securities | Mkt Outperform |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
| Oct-22-18 | Initiated | Wedbush | Outperform |
View All
Sutro Biopharma Inc Stock (STRO) Latest News
Why millennials buy Sutro Biopharma Inc. (S09) stock2025 Dividend Review & Precise Swing Trade Alerts - ulpravda.ru
Is Sutro Biopharma Inc. stock a buy for dividend growthEarnings Risk Report & Risk Managed Trade Strategies - ulpravda.ru
How risky is Sutro Biopharma Inc. stock nowJuly 2025 Trends & Verified Short-Term Trading Plans - ulpravda.ru
Sutro Biopharma, Inc. to Present at 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026 - Quiver Quantitative
Sutro Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Sutro Biopharma lays off dozens of employees in ‘strategic portfolio review’ - MSN
Growth Report: What consensus target says about Sutro Biopharma Inc S09 stockQuarterly Trade Report & Risk Adjusted Buy and Sell Alerts - moha.gov.vn
Sutro Biopharma, Inc. (NASDAQ:STRO) Given Average Recommendation of “Hold” by Analysts - Defense World
Sutro Biopharma, Inc. (NASDAQ:STRO) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates - sharewise.com
Treasury Yields: Can Sutro Biopharma Inc stock beat analyst upgradesGlobal Markets & Growth Focused Entry Reports - moha.gov.vn
Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 46% - simplywall.st
Sutro Biopharma (NASDAQ:STRO) Will Have To Spend Its Cash Wisely - Yahoo Finance
Sutro Biopharma, Inc. (NASDAQ:STRO) Held Back By Insufficient Growth Even After Shares Climb 46% - 富途牛牛
Sutro Biopharma Stock Pre-Market (+6.9%): Momentum From Analyst EPS Upgrade - Trefis
Sutro Biopharma FY2025 EPS Forecast Boosted by HC Wainwright - Defense World
FY2025 EPS Estimate for Sutro Biopharma Increased by Analyst - MarketBeat
Sutro Biopharma, Inc. (NASDAQ:STRO) Short Interest Down 85.9% in December - MarketBeat
Sutro Biopharma (NASDAQ:STRO) Given New $10.00 Price Target at HC Wainwright - Defense World
HC Wainwright Forecasts Strong Price Appreciation for Sutro Biopharma (NASDAQ:STRO) Stock - MarketBeat
STRO: HC Wainwright Raises Price Target by 400% Today | STRO Sto - GuruFocus
HC Wainwright & Co. Maintains Sutro Biopharma (STRO) Neutral Recommendation - Nasdaq
Is Sutro Biopharma Inc. stock a contrarian buyQuarterly Trade Summary & High Accuracy Investment Entry Signals - Улправда
How rising interest rates impact Sutro Biopharma Inc. stockJuly 2025 Analyst Calls & Expert Verified Stock Movement Alerts - Улправда
Can Sutro Biopharma Inc. stock continue upward trendQuarterly Profit Report & Accurate Buy Signal Alerts - Улправда
Aug Rallies: Why Sutro Biopharma Inc stock is trending among retail tradersPortfolio Update Summary & Growth Oriented Trading Recommendations - moha.gov.vn
Is Sutro Biopharma Inc. stock supported by strong cash flowsJobs Report & Free Long-Term Investment Growth Plans - DonanımHaber
Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines - marketscreener.com
Why Sutro Biopharma Inc. (S09) stock benefits from AI revolutionM&A Rumor & Risk Controlled Daily Plans - DonanımHaber
Is Sutro Biopharma Inc. stock undervalued vs historical averages2025 Breakouts & Breakdowns & Risk Adjusted Buy/Sell Alerts - Bölüm Sonu Canavarı
Is Sutro Biopharma Inc. stock cheap at current valuationQuarterly Risk Review & Free Technical Pattern Based Buy Signals - DonanımHaber
Bear Alert: Is Sutro Biopharma Inc. stock a contrarian buyPortfolio Return Summary & AI Powered Market Entry Ideas - ulpravda.ru
Is Sutro Biopharma Inc. (S09) stock ideal for retirement investorsWeekly Trend Summary & Stepwise Entry and Exit Trade Signals - Улправда
Sutro Biopharma regains Nasdaq compliance after meeting minimum bid price - Investing.com Australia
Sutro Biopharma regains Nasdaq compliance after reverse stock split - Investing.com India
Sutro Biopharma regains Nasdaq compliance after meeting minimum bid price By Investing.com - Investing.com South Africa
Sutro Biopharma Regains Nasdaq Listing Compliance - TipRanks
Sutro Biopharma regains Nasdaq compliance after reverse stock split By Investing.com - Investing.com South Africa
Sutro Biopharma Regains Nasdaq Compliance - TradingView — Track All Markets
[8-K] SUTRO BIOPHARMA, INC. Reports Material Event | STRO SEC FilingForm 8-K - Stock Titan
Free cash flow per share of Sutro Biopharma, Inc. – MUN:S090 - TradingView — Track All Markets
Sutro Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement - The Manila Times
Sutro Biopharma Regains Nasdaq Compliance Following Reverse Stock Split - Quiver Quantitative
Deutsche Bank Boosts Price Target on Sutro Biopharma to $51 From $5, Keeps Buy Rating - marketscreener.com
Sutro Biopharma regains NASDAQ listing compliance - MSN
CEO Chung Acquires 1,606 Of Sutro Biopharma Inc [STRO] - TradingView — Track All Markets
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates - MSN
Net margin % of Sutro Biopharma, Inc. – FWB:S090 - TradingView — Track All Markets
Sutro Biopharma Earnings Notes - Trefis
Check out Sutro Biopharma's stock price (S090-FF) in real time - CNBC
Sutro Biopharma Inc Stock (STRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.80%
4.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):